FORT MILLS, S.C., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, announced today that its previously announced 1-for-19 reverse stock split of its common stock became effective at 12:01 A.M. Eastern Time, on August 15, 2025. The Company's common stock will continue to be traded on the NYSE American under the symbol "VTAK" and will begin trading on a split-adjusted basis when the market opens on August 15, 2025. The new CUSIP number for the Company's common stock following the reverse stock split will be 74933X708.
Related Questions
Is there any correlation between the reverse split and upcoming corporate milestones, such as product approvals or financing events?
How will the 1‑for‑19 reverse stock split affect VTAK's share price and trading volume?
What is the expected impact of the reverse split on the company's market capitalization and float?
Will the split improve the stock's eligibility for inclusion in indices or institutional mandates?
How might the reverse split influence the perception of VTAK among retail and institutional investors?
Are there any historical precedents for similar reverse splits in the cardiac electrophysiology sector and what were the outcomes?
Will the new CUSIP number create any administrative or settlement issues for current shareholders?
What is the anticipated effect on liquidity and bid‑ask spreads post‑split?
How does the reverse split affect the company's ability to raise capital in the future?
Could the reverse split trigger any technical trading rules, such as short‑sale restrictions or margin requirements?